|
|
| Line 1: |
Line 1: |
| {{PBI|Dientamoeba fragilis}}
| |
| :*'''Dientamoeba fragilis infection'''<ref>{{citeweb|title=CDC Dientamoeba fragilis|url=http://www.cdc.gov/parasites/dientamoeba/health_professionals/index.html}}</ref><ref>{{cite book | last = Gilbert | first = David | title = The Sanford guide to antimicrobial therapy 2014 | publisher = Antimicrobial Therapy | location = Sperryville, Va | year = 2014 | isbn = 978-1930808782 }}</ref><ref>{{Cite journal| doi = 10.1016/j.ijpddr.2012.08.002| issn = 2211-3207| volume = 2| pages = 204–215| last1 = Nagata| first1 = Noriyuki| last2 = Marriott| first2 = Deborah| last3 = Harkness| first3 = John| last4 = Ellis| first4 = John T.| last5 = Stark| first5 = Damien| title = Current treatment options for Dientamoeba fragilis infections| journal = International Journal for Parasitology. Drugs and Drug Resistance| date = 2012-12| pmid = 24533282| pmc = PMC3862407}}</ref>
| |
| ::* Preferred regimen: [[Iodoquinol]] 650 mg PO tid for 20 days
| |
| ::* Alternative regimen (1): [[Tetracycline]] 500 mg PO qid for 10 days
| |
| ::* Alternative regimen (2): [[Metronidazole]] 500–750 mg PO three times daily for 10 days
| |
| ::* Alternative regimen (3): [[Paromomycin]] 25–35 mg/kg/day PO in three divided doses for 7 days
| |
| :::* 1.1 '''Treatment in pregnancy'''
| |
| ::::* Iodoquinol use in pregnancy is limited, and risk to the embryo-fetus is unknown, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
| |
| ::::* Metronidazole is in pregnancy category B. Data on the use of this drug in pregnant women are conflicting. The available evidence suggests use during pregnancy has a low risk of congenital anomalies. May be used during pregnancy in those patients who will clearly benefit from the drug, although its use in the first trimester is generally not advised.
| |
| ::::* Oral dose of Paromomycin generally is poorly absorbed from the gastrointestinal tract, with minimal, if any, systemic availability.
| |
|
| |
|
| :::* 1.2 '''Treatment during lactation'''
| |
| ::::* Iodoquinol should be used with caution in breastfeeding women.
| |
| ::::* Metronidazole should be used during lactation only if the potential benefit of therapy to the mother justifies the potential risk to the infant.
| |
| ::::* Oral dose of Paromomycin is unlikely to be excreted in breast milk, and the drug generally is poorly absorbed from the gastrointestinal tract.
| |
| :::* 1.3 '''Treatment in pediatric patients'''
| |
| ::::* [[Iodoquinol]] 30–40 mg/kg/day (maximum 2 g) PO in 3 doses for 20 days. The safety of iodoquinol in children has not been established.
| |
| ::::* [[Tetracycline]] 40 mg/kg/day (maximum 2 g) PO in 4 doses for 10 days
| |
| ::::* [[Metronidazole]] 35–50 mg/kg/day PO in 3 doses for 10 days. The safety in children has not been established, is listed as an antiamebic and antigiardiasis medicine on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
| |
| ::::* [[Paromomycin]] 25–35 mg/kg/day PO in 3 doses for 7 days. The safety of oral dose in children has not been formally evaluated. However, the safety profiles likely are comparable in children and adults.
| |
|
| |
|
| ==References== | | ==References== |
| {{reflist}} | | {{reflist}} |